Cannara Biotech Cash Flow Statement

Financials in millions CAD. Fiscal year is September - August.

Millions CAD. Fiscal year is Sep - Aug.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Net Income	13.08	6.44	6.95	2.31	-1.53
Depreciation & Amortization	6.68	6.35	4.94	3.92	3.03
Stock-Based Compensation	1.19	1.98	1.75	0.35	0.33
Other Adjustments	5.36	-1.59	-2.09	-1.17	-0.1
Changes in Other Operating Activities	-6.3	-2.5	-5.64	-11.48	-3.82
Operating Cash Flow	20.01	10.68	5.91	-6.08	-2.09
Operating Cash Flow Growth	87.34%	80.72%	-	-	-
Capital Expenditures	-6.36	-7.47	-9.88	-15.47	-31.07
Sale of Property, Plant & Equipment	0.16	2.12	0.19	0.06	0.22
Other Investing Activities	0.25	0.16	0.21	0.06	0.03
Investing Cash Flow	-5.95	-5.19	-9.48	-15.35	-30.83
Short-Term Debt Issued	0.5	5.7	3	-	-
Short-Term Debt Repaid	-0	-2.44	-	-	-
Net Short-Term Debt Issued (Repaid)	0.5	3.26	3	-	-
Long-Term Debt Issued	-	-	-	61.32	10.7
Long-Term Debt Repaid	-2.73	-1.97	-1.97	-34	-0
Net Long-Term Debt Issued (Repaid)	-2.73	-1.97	-1.97	27.32	10.7
Issuance of Common Stock	-	-	0.05	0.05	24.66
Repurchase of Common Stock	-	-0.28	-0.37	-	-
Net Common Stock Issued (Repurchased)	-	-0.28	-0.32	0.05	24.66
Other Financing Activities	-4.09	-4.16	-4.9	-1.9	-2.11
Financing Cash Flow	-6.32	-3.14	-4.19	25.46	33.25
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-0.08	-0.08	0.06
Net Cash Flow	7.74	2.35	-7.76	4.04	0.33
Free Cash Flow	13.65	3.21	-3.97	-21.55	-33.17
Free Cash Flow Growth	324.86%	-	-	-	-
FCF Margin	12.72%	3.91%	-6.89%	-59.85%	-192.08%
Free Cash Flow Per Share	0.15	0.04	-0.04	-0.25	-0.43
Levered Free Cash Flow	4.86	4.12	-2.6	6.59	-22.7
Unlevered Free Cash Flow	22.38	2.07	1.31	-18.09	-31.61

Updated Aug 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.